From Recognition to Resolution: A Practical Framework for Diagnosing, Treating, and Managing MASH in the Liver/GI Specialty Setting

Nov 05 2026

Convention Center: Four Seasons Ballroom 1

12:00 PM - 1:30 PM

CE Credits

World Class Speakers

Description

MASH, the progressive, inflammatory form of MASLD, is an increasing cause of end-stage liver disease. The therapeutic landscape has transformed with FDA approvals of resmetirom and semaglutide; optimal agent selection is complex. FGF21 analogs are in clinical development. This program is designed for those who manage patients with MASH.

CE: 1.5 CME Hours
Supported by: Novo Nordisk
Organized by: Voxmedia LLC
For more information and to register, visit: https://symposiareg.com/22614/

Objectives

Apply the AASLD-endorsed stepwise non-invasive testing framework including FIB-4, VCTE/ELF, and MRE to identify patients with MASH and significant fibrosis (F2F3) who are candidates for pharmacotherapy, and describe the role of liver biopsy in cases of diagnostic uncertainty
Compare the mechanism of action, Phase 3 clinical evidence, patient selection criteria, and monitoring requirements for resmetirom and semaglutide 2.4 mg/week in patients with non-cirrhotic MASH and F2F3 fibrosis, and apply this comparison to individualized treatment decisions based on patient comorbidity profile
Characterize the FGF21 analog class including efruxifermin and pegozafermin by mechanism of action, Phase 2 and Phase 3 evidence to date, and current regulatory status, and describe the evidence supporting the investigational role of FGF21 analogs in patients with pre-cirrhotic MASH and compensated cirrhosis due to MASH

From Recognition to Resolution: A Practical Framework for Diagnosing, Treating, and Managing MASH in the Liver/GI Specialty Setting

World Class Speakers

Arun Sanyal

Rohit Loomba

Mary E. Rinella

Mazen Noureddin

Description

Objectives